Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer

Archives of Gynecology and Obstetrics

Volumn 293, Issue 3, 2016, Pages 645-650

  Paek, Jiheum ^a,b   Lee, Maria ^c   Nam, Eun Ji ^d   Kim, Sang Wun ^d   Kim, Young Tae ^d  

^a Ajou University School of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Epithelial ovarian cancer; HMGB1; Prognosis; Progression free survival

Indexed keywords

CARBOPLATIN; HIGH MOBILITY GROUP B1 PROTEIN; PACLITAXEL; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TISSUE MICROARRAY; AGED; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRIDGED COMPOUNDS; CYTOREDUCTION SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84958778210     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-3864-1     Document Type: Article

References (25)

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
2. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC Jr, Ritts RE (1988) Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 159:341–346
3. Jacobs I, Bast RC Jr (1989) The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4:1–12
4. Wang L, Kong B (2015) Analysis of the association of matrix metalloproteinase-1 gene promoter (rs1799750) polymorphism and risk of ovarian cancer. Int J Gynecol Cancer 25:961–967
5. Tiwari A, Ocon-Grove OM, Hadley JA, Giles JR, Johnson PA, Ramachandran R (2015) Expression of adiponectin and its receptors is altered in epithelial ovarian tumors and ascites-derived ovarian cancer cell lines. Int J Gynecol Cancer 25:399–406
6. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287:1671–1679
7. Beyazit F, Ayhan S, Celik HT, Gungor T (2015) Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer. Arch Gynecol Obstet 292:415–420
8. Wilailak S, Chan KK, Chen CA, Nam JH, Ochiai K, Aw TC, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Charakorn C, Sumpaico WW (2015) Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. J Gynecol Oncol 26:46–53
9. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342
10. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E (2004) Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 40:120–130
11. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28:367–388
12. Srinivasan M, Banerjee S, Palmer A, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A, Kalyanasundaram R, Munirathinam G (2014) HMGB1 in hormone-related cancer: a potential therapeutic target. Horm Cancer 5:127–139
13. Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, Bullerdiek J (2001) Variation of HMGB1 expression in breast cancer. Anticancer Res 21:3881–3885
14. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196:163–170
15. Kuniyasu H, Chihara Y, Takahashi T (2003) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10:445–448
16. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R (2003) Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 10:1863–1868
17. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y (2004) Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 51:928–930
18. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ (2008) Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 40:446–452
19. Chen J, Xi B, Zhao Y, Yu Y, Zhang J, Wang C (2012) High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol 126:109–117
20. Li Y, Tian J, Fu X, Chen Y, Zhang W, Yao H, Hao Q (2014) Serum high mobility group box protein 1 as a clinical marker for ovarian cancer. Neoplasma 61:579–584
21. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:354–360
22. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251
23. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081
24. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
25. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A (2005) Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26:293–301